Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
  • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
  • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
  • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
  • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Definitions

• This invention relates to 2-amino and 2-nitro benzamides, and more particularly to basically substituted alkoxy anthranilamides, their corresponding 2-nitro compounds and the nontoxic salts of all such compounds.
• the basically substituted alkoxy anthranilamides of this invention are new compounds having the following formula:
• R is lower alkyl, phenyl or substituted phenyl in which the substituent is halogen, lower alkyl, lower alkoxy or trifluoromethyl;
• R is nitro or amino;
• R R R and R are hydrogen, lower alkoxy or methylenedioxy, at least one of R R R and R being a lower alkoxy or connected to a methylenedioxy group; and
• n is a whole number within the range of 2 through 4.
• the lower alkoxy and lower alkyl groups have less than 4 carbon atoms.
• the halogen of the substituted phenyl may be, for example, fluorine or chlorine.
• Either or both hydrogens of the amino group in the 2 position of the benzene nucleus may be substituted, for example, with lower alkyl or lower acyl.
• the compounds of this invention manifest central nervous system depressant activity in many animals in dosages from 30 to 300 mg. per kg. of body weight. They possess antipsychotic characteristics. They are also useful'as sedatives and transquilizers in the treatment of animals.
• mice Compounds of this invention were screened in mice by the Irwin Screening Protocol in accordance with the procedure described in a paper presented at the Postgraduate Course on Animal and Clinical Pharmacological Techniques in Drug Evaluation at Hahnemann Medical College and Hospital of Philadelphia, Feb. 4-15, 1963, published by Year Book Medical Publishers, 1963. The results indicate the compounds are potent central nervous system depressants with memo-pharmacological profiles resembling that of chlorpromazine.
• compositions of this invention may be produced by reacting the corresponding 2-nitro substituted benzoyl chloride with the required amine in accordance with the following reaction:
• the basically substituted alkoxy anthranilamides are produced from the corresponding Z-nitro compound by catalytic reduction with a suitable catalyst, such as Raney nickel or palladium-on-carbon in accordance with the following reaction:
• R COOI-I SOC 35- COCl l R0 R5
• the required amine used as the other reactant to produce the 2-nitro compound corresponding to the basically substituted alkoxy anthranilamides is prepared by reacting a l-substituted piperazine with a chloronitrile and anhydrous sodium carbonate in a suitable solvent such as isopropanol in accordance with the method of Shin Hayao and R. N. Schut J. Org. Chem. 24, 3414 (1961). The reaction is as follows:
• an unsaturated nitrile such as acrylonitrile may be employed instead of the chloronitrile.
• This alternative method is a modification of the procedure of C. B. Pollard, E. G. Rietz and R. Robbins, J. Am. Chem. Soc., 75, 2989 (1953).
• the required amine is prepared from the cyano compound by reduction with lithium aluminum hydride in accordance with the following reaction:
• Mono-, diand trinon-toxic acid addition salts of the basically substituted alkoxy anthranilamides and monoand dinon-toxic acid addition salts of the corresponding nitro compounds of such anthranilamides are produced by mixing stoichiometric amounts of the required anthranilamide or its corresponding 2-nitro compound and the required acid in an inert solvent such as ether, ethanol, benzene or toluene, and subsequently filtering the precipitated salt or evaporating the solvent and recovering the solid residue.
• an inert solvent such as ether, ethanol, benzene or toluene
• Salts of inorganic acids such as hydrochloric, sulfuric or phosphoric acid or salts of organic acids, such as acetic, succinic, tartaric or citric acid of the basically substituted alkoxy anthranilamides or their corresponding 2-nitro compounds may be produced in this manner.
• the compounds of this invention such as the basically substituted alkoxy anthranilamides of Examples I thru XXXIII are associated with solid or liquid pharmaceutically acceptable carriers for oral or parenteral administration in the treatment of behavior disturbances in animals.
• the compounds and carriers may be in the form of capsules, tablets, powders, sterile solutions of water or other pharmaceutically acceptable solvent or other dosage for-ms.
• the compounds may be admixed with diluents and adjuvents, such as lactose, gums, stearic acid or talc.
• the residue was dissolved in methylene chloride (500 ml.) and the solution was extracted successively with 50% sodium hydroxide solution (50 ml.) and water.
• the methylene chloride solution was dried over sodium sulfate, filtered, and evaporated to dryness under reduced pressure.
• the residue was recrystallized twice from a mixture of isopropanol and hexane to give 6.1 g. (49.1% yield) of double melting yellow needles, M.P. 75-78 C. and 137-138" C.
• the analytical sample was recrystallized from a mixture of ethyl acetate and hexane as yellow needles, M.P. -136 C.
• zine This compound was prepared by a modification of the method of Shin Hayao and R. N. Schut, 10c. cit., by heating on the steam bath for 20 hours a mixture of 1- (p-methoxyphenyl) piperazine (18.5 g., 0.097 mole) and acrylonitrile (6.3 g., 0.12 mole). The crystalline reaction mass was recrystallized from ethanol to give 20.0 g. (87.0% yield) of colorless crystals, M.P. 79-80 C.
• the crude material was recrystallized from isopropanol to give 21.0 g. (89.4% yield) of tan needles, M.P. 9293 C.
• the analytical sample was twice recrystallized from a mixture of isopropanol and hexane as colorless needles, M.P. 92- 93 C.
• the trihydrochloride was prepared by adding dry hydrogen chloride to a solution of the amine in ether and recrystallizing the filter cake from a mixture of ethanol and ether to give a white solid, M.P. -190" C.
• the mixture was stirred for 18 hours at ambient temperature, filtered, and the filter cake was recrystallized from a hot mixture of 30% aqueous sodium hydroxide solution (25 ml.) and isopropanol (250 ml.).
• the isopropanol solution was decanted from the lower aqueous phase and upon cooling deposited 10.6 g. (76% yield) of yellow needles, M.P. 170-172 C.
• the analytical sample was recrystallized from isopropanol solution as yellow needles, M.P. 172-174 C.
• the filter cake was recrystallized from a mixture of 30% aqueous sodium hydroxide solution ml.) and isopropanol (250 ml.).
• the hot supernatant isopropanol solution was decanted and cooled to give 5.4 g. (47% yield) of colorless needles, M.P. 151153 C.
• the analytical sample was recrystallized from isopropanol as colorless needles, M.P. 152- 153" C.
• the mixture was stirred for 18 hours at ambient temperature and filtered.
• the filter-cake was recrystallized from a mixture of 20% aqueous sodium hydroxide solution (50 m1.) and isopropanol (250 ml.).
• the hot supenatant isopropanol solution was decanted and cooled to give 8.0 g. (67% yield) of pale yellow needles, M.P. 103-104 C.
• the analytical sample was recrystallized from ethyl acetate as colorless needles, M.P. 103-104 C.
• the mixture was stirred for 18 hours at ambient temperature and filtered.
• the filter-cake was recrystallized from a mixture of 20% aqueous sodium hydroxide solution (50 ml.) and isopropanol (250 ml.).
• the hot supernatant isopropanol solution was decanted and cooled to give 5.0 g. (47.7% yield) of pale yellow crystals, M.P. 131-132 C.
• the analytical sample was recrystallized from isopropanol was pale yellow platelets, M.P. 133- 134 C.
• the filter-cake was recrystallized from a mixture of 30% aqueous sodium hydroxide solution (50 ml.) and hot isopropanol (500 ml.).
• the hot supernatant isopropanol solution was decanted and cooled to give a tan solid which was recrystallized from a mixture of ethyl acetate and hexane to give 9.2 g. (45.1% yield) of pale yellow crystals, M.P. 104-106 C.
• the analytical sample was recrystallized from a mixture of ethyl acetate and hexane, M.P. 105- 106 C.
• the mixture was stirred for 1 hour at ambient temperature and filtered.
• the filter-cake was recrystallized from a mixture of 30% aqueous sodium hydroxide solution (50 ml.) and hot isopropanol (500 ml.)
• the hot supernatant isopropanol solution was decanted and cooled to give a light pink solid which was recrystallized from isopropanol to give 11.0 g. (52.1% yield) of pale yellow platelets, M.P. 178-180 C.
• The-analytical sample was recrystallized from ethyl acetate as pale yellow platelets, M.P.180-181" C.
• the resultant suspension was stirred for 1 hour, filtered and dissolved in water.
• the solution was made basic with 50% sodium hydroxide solution and extracted with methylene chloride.
• the methylene chloride extracts were dried over sodium sulfate, filtered and evaporated to dryness under reduced pressure.
• the residue was recrystallized from a mixture of ethyl acetate and hexane to give 10.4 g. (60.1% yield) of pale yellow solid, M.P. -107 C.
• the analytical sample was recrystallized from a mixture of ethyl acetate and hexane as colorless needles, M.P. 106-l07 C.
• the mixture was stirred for 18 hours at ambient temperature, filtered, and the filter-cake was recrystallized from a hot mixture of 30% aqueous sodium hydroxide solution and isopropanol.
• the hot supernatant isopropanol solution was decanted and cooled to give 8.9 g. (67% yield) of yellow crystals, M.P. l70172 C.
• the analytical sample was recrystallized from ethyl acetate as pale yellow needles, M.P. 170-171.5 C.
• the filter-cake was recrystallized from a hot mixture of 30% aqueous sodium hydroxide solution and isopropanol (300 ml.). The hot supernatant isopropanol solution was decanted and cooled to give 8.2 g. (69.5% yield) of yellow needles, M.P. 167 C. The analytical sample was recrystallized from ethyl acetate as pale yellow needles, M.P. 167- 168 C.
• the filter-cake was dissolved in 10% aqueous sodium hydroxide solution (125 ml.) and the solution was extracted with methylene chloride. After drying over sodium sulfate, the methylene chloride solution was evaporated to dryness under reduced pressure. The residue was recrystallized from a mixture of ethyl acetate and hexane to give 8.4 g. (63.6% yield) of yellow crystals, M.P. 142-143 C. The analytical sample was recrystallized from isopropanol as pale yellow platelets, M.P. 143-144 C.
• the filter-cake was recrystallized from a hot mixture of 30% aqueous sodium hydroxide solution and isopropanol.
• the hot supernatant isopropanol solution was decanted and cooled to give 10.3 g. (860% y e at colo ess need e M.P. 15 -1523 20
• the analytical sample was recrystallized from ethyl acetate as colorless needles, M.P. 150-151.5 C.
• the filter-cake was recrystallized from a hot mixture of 30% aqueous sodium hydroxide solution and isopropanol.
• the hot supernatant isopropanol solution was decanted and cooled to give 10.6 g. (88.4% yield) of pale yellow needles, M.P. 144-146 C.
• the analytical sample was recrystallized from ethyl acetate as pale yellow needles, M.P. 145146 C.
• the filter-cake was recrystallized from a mixture of 30% aqueous sodium hydroxide solution (50 ml.) and hot isopropanol (300 ml.). The hot supernatant isopropanol solution was decanted and cooled to give 14.3 g. (88.8% yield) of yellow needles, M.P. 169-170 C.
• the analytical sample was recrystallized from ethyl acetate as pale yellow platelets, M.P. 169-170 C.
• the filter-cake was dissolved in 10% aqueous sodium hydroxide solution (125 ml.) and the solution was extracted with methylene chloride. After drying over sodium sulfate, the methylene chloride solution was evaporated to dryness under reduced pressure. The residue was recrystallized from a mixture of ethyl acetate and hexane to give 10.2 g. (77.2% yield) of pale yellow needles, M.P. 105-107 C. The analytical sample was recrystallized from ether as off-white needles, M.P. 108-109 C.
• the catalyst was filtered off and the filtrate was cooled to give 2.2 g. (95.6% yield) of colorless platelets, M.P. 148- 150 C.
• the analytical sample was recrystallized from ethyl acetate as colorless platelets, M.P. 149-150 C.
• the mixture was stirred for 3 hours at ambient temperature and filtered.
• the filter-cake was recrystallized from a hot mixture of 30% aqueous sodium hydroxide (50 ml.) and isopropanol (500 ml.).
• the hot supernatant isopropanol solution was decanted and cooled to give a tan solid which was recrystallized from a mixture of ethyl acetate and hexane to give 10.1 g. (63.5% yield) of pale yellow needles, M.P. 176-179 C.
• the analytical sample was recrystallized from ethyl acetate as pale yellow needles, M.P. 179-181 C.
• the ether solution was treated with excess hydrogen chloride to give a hygroscopic solid which was recrystallized from a mixture of methol, ethyl acetate and ether to give 0.9 g. (65% yield) of yellow solid, M.P. 178 184 C.
• the analytical sample was twice recrystallized from a mixture of methanol and ethyl acetate (charcoal) as colorless needles of a hydrate, M.P. 183187 C.
• composition of the invention may be combined with pharmaceutically acceptable carriers to produce desireddosage unit forms.
• pharmaceutically acceptable carriers for example, 2-amino-4,5-dimethoxy-N-[3-(4-phenyl-l-piperazinyl) propyl] benzamide monohydrochloride may be produced in different dosage unit forms, such as difierent types of tablets, capsules and injectables.
• .T he following is a tablet formulation which is utilized in situations in which the presence of water is not desirable or may contribute to the instability of the resulting tablet.
• the mix ture containing the benzamide is granulated with the ethyl cellulose solution.
• Anhydrous ethyl alcohol may be added at this stage to obtain satisfactory wet granules.
• the mixture is wet screened through an appropriate size screen, for example #8 stainless steel screen, and the granulations are dried at room temperature.
• the mixture is then dry screened through a #20 stainless steel screen.
• the remaining starch, talc, and magnesium stearate are incorporated 25 by mixing thoroughly with the other ingredients.
• the mixture is then incorporated in tablets.
• the following formulation utilizes as a granulation procedure, the pm-compression or slugging method. Such procedure is conducted in the absence of water and non-aqueous liquids.
• the formulation is as follows:
• Tabletting when a small percentage of active benzamide is incorporated may be achieved by direct compression. Several methods are available for this purpose. Two methods are illustrated in this example.
• Another method of direct compressed tablet involves the utilization of commercially available mixtures such as that sold under the name Emcompress, manufactured by Edward Mendell Co. This mixture has all the necessary ingredients of the tablet, such as the diluent, disintegrant and lubricant added to it.
• Emcompress manufactured by Edward Mendell Co.
• Emcompress manufactured by Edward Mendell Co.
• This mixture has all the necessary ingredients of the tablet, such as the diluent, disintegrant and lubricant added to it.
• a typical formula press is as follows:
• the benzamide may be incorporated in the Emcompress as in the following formulation:
• procaine hydrochloride benzalkonium chloride
• sufiicient sodium chloride to obtain isotonicity
• the benzamide are added together.
• the product is manufactured under sterile conditions, filtered and filled into suitable containers, either single dose ampules or multi-dose vials.
• composition of matter selected from the class consisting of basically substituted alkoxy anthranilamides, their corresponding 2-nitro compounds, and non-toxic acid addition salts of all such compounds, said basically substituted alkoxy anthranilamides having the formula:
• R R R or R being a lower alkoxy or connected to a methylenedioxy group; and n is a whole number within the range of 2 through 4.
• composition of matter in accordance with claim 1 in which the compound is 2-amino-4,5--dimethoxy-N-[3- [4-(o-tolyl)- l-piperazinyl] propyl] benzamide or the non-toxic addition salts thereof.
• composition of matter in accordance with claim 1 in which the compound is 2-amino-4,5-dimethoxy-N-[3- [4-(m-tolyl)-l-piperazinyl] propyl] benzamide or the non-toxic addition salts thereof.
• composition of matter in accordance with claim 1 in which the compound is 2-amino-4,5-dimethoxy-N-[3- [4-(p-methoxyphenyl)-1-piperazinyl] propyl] benzamide or the non-toxic addition salts thereof.
• composition of matter in accordance with claim 1 in which the compound is 2-amino-4,5-dimethoxy-N-[3- [4-(o-chlorophenyl)-l-piperazinyl] propyl] benzamide or the non-toxic addition salts thereof.
• composition of matter in accordance with claim 1 in which the compound is 2-amino-4,5-dimethoxy-N-[3- [4-(m-chlorophenyl)-l-piperazinyl] propyl] benzamide or the non-toxic addition salts thereof.
• composition of matter in accordance with claim 1 in which the compound is 2-amino-4,5-dimethoxy-N-[3- [4-(p-chloropheny1)-1-piperazindyl] propyl] benzamide or the non-toxic addition salts thereof.
• composition of matter in accordance with claim 1 in which the compound is 2-amino-3-methoxy-N-[3- (4-phenyl-1-piperazinyl) propyl] benzamide or the nontoxic addition salts thereof.
• composition of matter in accordance with claim 1 in which the compound is 2-amino-4,5-diethoxy-N-[3- (4-phenyl-1-piperazinyl) propyl] benzamide or the nontoxic addition salts thereof.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Pyridine Compounds (AREA)
• Hydrogenated Pyridines (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=27079494

Family Applications (2)

Family Applications After (1)

Country Status (6)

Cited By (5)

Families Citing this family (3)

Citations (1)

• 1966
  • 1966-10-11 US US585748A patent/US3488352A/en not_active Expired - Lifetime
• 1967
  • 1967-10-04 GB GB45301/67A patent/GB1198459A/en not_active Expired
  • 1967-10-05 DE DE19671695783 patent/DE1695783A1/de active Pending
  • 1967-10-11 CH CH1417567A patent/CH505836A/de not_active IP Right Cessation
  • 1967-10-11 FR FR124132A patent/FR7073M/fr not_active Expired
  • 1967-10-11 FR FR1570446D patent/FR1570446A/fr not_active Expired
  • 1967-10-11 NL NL6713798A patent/NL6713798A/xx unknown
• 1969
  • 1969-05-16 US US42056*[A patent/US3574839A/en not_active Expired - Lifetime

Patent Citations (1)

Also Published As

Similar Documents